ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
+0.92 (2.40%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.33 - 39.36
52 week 28.60 - 51.99
Open 38.51
Vol / Avg. 577,317.00/1.34M
Mkt cap 3.96B
P/E     -
Div/yield     -
EPS -1.47
Shares 100.91M
Beta 3.53
Inst. own 99%
Feb 24, 2016
Q4 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 10, 2015
ACADIA Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 5, 2015
Q3 2015 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Nov 5, 2015
Q3 2015 ACADIA Pharmaceuticals Inc Earnings Release
Sep 29, 2015
ACADIA Pharmaceuticals Inc at Ladenburg Thalmann Life Sciences Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -99758.98% -77062.50%
Operating margin -99994.88% -77691.66%
EBITD margin - -77520.00%
Return on average assets -59.92% -35.94%
Return on average equity -64.60% -37.62%
Employees 151 -
CDP Score - -


3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis, Alzheimer’s disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Chief Financial Officer, Director
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Torsten Erik Rasmussen Independent Director
Age: 70
Bio & Compensation  - Reuters